Retroperitoneal Inflammation Detected on FDG PET/CT in Patient on Long-Term Immunotherapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 36728374.
- Also identified by DOI 10.1097/RLU.0000000000004513.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 68-year-old man with a history of pulmonary adenocarcinoma on maintenance pembrolizumab presented for surveillance imaging. 18 F-FDG PET/CT demonstrated new ill-defined right retroperitoneal and presacral soft tissue stranding with associated FDG uptake suggestive of inflammation. Biopsy results revealed fibroadipose tissue with extensive lymphoplasmacytic inflammation concerning for immunotherapy-related toxicity. The patient was subsequently taken off pembrolizumab, which he had been on for approximately 3 years. Recognition of immunotherapy-related adverse effects and how they can manifest on 18 F-FDG PET/CT is important for prompt cessation of treatment.
Medical subject headings
- Positron Emission Tomography Computed Tomography
- Lung Neoplasms